Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Treasury Shares (2016 - 2019)

Historic Treasury Shares for Celldex Therapeutics (CLDX) over the last 9 years, with Q4 2019 value amounting to $1110.0.

  • Celldex Therapeutics' Treasury Shares fell 6875.0% to $1110.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $1110.0, marking a year-over-year decrease of 6875.0%. This contributed to the annual value of $1110.0 for FY2019, which is 6875.0% down from last year.
  • Celldex Therapeutics' Treasury Shares amounted to $1110.0 in Q4 2019, which was down 6875.0% from $3552.0 recorded in Q4 2018.
  • Celldex Therapeutics' Treasury Shares' 5-year high stood at $50000.0 during Q4 2016, with a 5-year trough of $1110.0 in Q4 2019.
  • Over the past 5 years, Celldex Therapeutics' median Treasury Shares value was $6445.0 (recorded in 2017), while the average stood at $16121.4.
  • Per our database at Business Quant, Celldex Therapeutics' Treasury Shares soared by 17857.14% in 2015 and then plummeted by 8711.0% in 2017.
  • Celldex Therapeutics' Treasury Shares (Quarter) stood at $19500.0 in 2015, then skyrocketed by 156.41% to $50000.0 in 2016, then plummeted by 87.11% to $6445.0 in 2017, then crashed by 44.89% to $3552.0 in 2018, then plummeted by 68.75% to $1110.0 in 2019.
  • Its Treasury Shares stands at $1110.0 for Q4 2019, versus $3552.0 for Q4 2018 and $6445.0 for Q4 2017.